Form 4: Gilead CFO Dickinson Reports RSU Vesting & Tax Sale

Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., reported transactions on September 10, 2025.
• Acquired 3,696 shares of common stock upon the vesting of restricted stock units.
• Disposed of 1,751 shares of common stock at a price of $115.25 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Dickinson beneficially owns 162,055 shares of common stock directly.
• The restricted stock units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and the balance vesting 6.25% quarterly thereafter.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (RSU vesting and tax-related share disposal) which are expected and do not indicate any significant positive or negative operational or financial developments for the company.

Positives

• Vesting of 3,696 restricted stock units indicates continued long-term incentive alignment for the Chief Financial Officer.
• The acquisition of shares increases the CFO's direct ownership in the company, demonstrating confidence.

Negatives

• Disposal of 1,751 shares, although for tax purposes, reduces the direct beneficial ownership of the Chief Financial Officer.

Future Outlook

The filing details a routine vesting schedule for restricted stock units, indicating future vesting events will occur quarterly until fully vested, aligning executive compensation with long-term company performance.

Industry Context

This is a standard insider transaction report for a Chief Financial Officer, common across all industries, reflecting the routine compensation structure involving equity awards in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Gilead Sciences.

Comparison to Industry Standards

• The vesting schedule of restricted stock units (25% on first anniversary, then 6.25% quarterly) is a common practice for executive compensation in the pharmaceutical industry, similar to structures seen at companies like Pfizer, Merck, or Johnson & Johnson, designed to incentivize long-term retention and performance.

Stakeholder Impact

• Shareholders: Minor impact as these are routine compensation-related transactions and do not reflect a change in company fundamentals or strategy.
• Employees: No direct impact on the broader employee base, but reflects standard executive compensation practices.

Next Steps

• Future vesting of remaining restricted stock units will occur quarterly, with 6.25% of the balance vesting each quarter until fully vested.

Key Dates

Keywords

Gilead Sciences, GILD, Andrew D. Dickinson, Chief Financial Officer, CFO, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Beneficial Ownership